Scarica l'app Stockscreener
13.96
3.10%
0.42
Dopo l'orario di chiusura:
14.00
0.04
+0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics stock hits 52-week low at 12.52 USD By Investing.com - Investing.com Canada
SMMT|Summit Therapeutics Inc|Price:13.105|Chg%:-0.555 - TradingKey
Summit Therapeutics Inc (SMMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm - Morningstar
Summit Therapeutics Inc (SMMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Summit Therapeutics Inc (SMMT) Cash Flow - TradingKey
Summit Therapeutics officers investigated for p... - Pluang
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations - The Globe and Mail
Piper Sandler Keeps Their Hold Rating on Summit Therapeutics (SMMT) - The Globe and Mail
SMMT|Summit Therapeutics Inc|Price:13.660|Chg%:-1.320 - TradingKey
Summit Therapeutics (SMMT) Analyst Maintains Neutral Rating Afte - GuruFocus
SMMT Maintained by Guggenheim -- Price Target Lowered to $38.00 - GuruFocus
SMMT Maintained by Stifel -- Price Target Lowered to $38.00 - GuruFocus
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.06, Implies 94% Upside - TradingView
Summit Therapeutics Establishes $380 Million ATM Equity Program - The Globe and Mail
Jefferies Cuts Summit Therapeutics Price Target to $15 From $17, Hold Rating Kept - marketscreener.com
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.2, Implies 95% Upside - TradingView
SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data - Stocktwits
Summit Therapeutics Flags Going Concern Risk Over Cash Needs - Benzinga
Summit Therapeutics Inc. Revenue Breakdown – NASDAQ:SMMT - TradingView
Stifel cuts Summit Therapeutics stock price target on timing concerns By Investing.com - Investing.com Canada
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus - TradingView
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 - BioSpace
Guggenheim lowers Summit Therapeutics stock price target on trial timing By Investing.com - Investing.com Canada
Summit Therapeutics Signs Distribution Agreement With J.P. Morgan Securities for Common Stock Offering - Minichart
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - Benzinga
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug - Yahoo Finance
Summit (SMMT) Completes Enrollment in Global HARMONi-3 Study - GuruFocus
Summit Therapeutics (SMMT) Reports Q2 EPS Beat with Strong Cash Position - GuruFocus
Summit Q2 2026 slides: ivonescimab OS data strengthens amid spending rise - Investing.com Nigeria
Summit Therapeutics (SMMT) Faces Financial Uncertainty Amid Funding Challenges - GuruFocus
Summit Therapeutics (SMMT) Reports Positive Clinical Developments and Strong Cash Position - GuruFocus
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance UK
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: - GuruFocus
Summit Therapeutics Launches $380 Million At-the-Market Equity Offering Program with J.P. Morgan Securities - Kalkine Media
Summit Therapeutics Announces Q2 2026 Financial Results and Operational Highlights - Kalkine Media
Summit Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Summit (SMMT) Advances Clinical Trials with Promising Ivonescima - GuruFocus
Summit Therapeutics (SMMT) Faces Funding Challenges Amid Q2 Losses - GuruFocus
Concerns Rise for Summit Therapeutics (SMMT) Regarding Financial Viability - GuruFocus
Summit Therapeutics (SMMT) Updates Phase III Survival Data, Is The Stock Still A Bargain? - Yahoo Finance
SMMT Q2 FY2026 earnings call - finance.biggo.com
[SMMT Q2 2026 Earnings Call] Summit Therapeutics Cash Hits $690.7M, Updated HARMONi Data Shows HR 0.76 Overall Survival Ahead of PDUFA - finance.biggo.com
Summit Therapeutics Initiates $380 Million At-The-Market Stock Offering with J.P. Morgan - Kalkine Media
Earnings call transcript: Summit Therapeutics Q2 2026 loss widens as shares fall after hours - Investing.com Canada
SMMT: Summit Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Summit Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SMMT) 2026-07-23 - Seeking Alpha
Summit Therapeutics Q2 Earnings Call Highlights - TradingView
Transcript : Summit Therapeutics Inc., Q2 2026 Earnings Call, Jul 23, 2026 - marketscreener.com
Summit Therapeutics says cash crunch could impact its ability to continue - Seeking Alpha
Summit Therapeutics (SMMT) Q2 2026 earnings summary - Quartr
Summit Therapeutics Reports Ivonescimab Progress and Strong Cash - TipRanks
Summit Therapeutics (SMMT) sets up $380M at-the-market share offering - Stock Titan
Summit Therapeutics Inc. (SMMT) Q2 FY2026 earnings call transcript - Yahoo Finance
1.84%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):